Sagent Pharmaceuticals

Sagent Pharmaceuticals®, a subsidiary of the Nichi-Iko Group, is a manufacturer of pharmaceutical injectables and biosimilars.[1] Sagent’s internal and external manufacturing offer flexibility in their product portfolio across diverse therapeutic categories and in packaging including vials, syringes and premix bags.

Sagent Pharmaceuticals
TypeSubsidiary
IndustryPharmaceuticals
Founded2007
HeadquartersSchaumburg, IL USA
Key people
Peter Kaemmerer (CEO)
Jeff Greve (CFO)
Websitesagentpharma.com

Sagent offers more than 60 injectable products across the anti-infective, oncology and critical care categories. All of Sagent’s products feature PreventIV Measures packaging and labeling, Sagent’s approach to packaging and labeling that may help reduce the risk of medication errors.

Company history

In 2007, Sagent was formed and launched its first injectable product.[2]

In 2011, the company filed for IPO offering 5,750,000 shares of common stock at a price of $16 per share.[3]

In 2014, the company purchased Omega Laboratories Limited and launched its first specialty pharmaceutical product.[4][5]

In 2015, the company sold Sagent (China) Pharmaceuticals to Nanjing King-Friend Biochemical Pharmaceutical Co.[6]

In 2016, the company was acquired by Nichi-Iko Pharmaceuticals.[1]

In 2019, the company acquired a sterile injectable plant in Raleigh, NC. Omega Laboratories Limited received FDA approval to manufacture sterile injectable products for the US market. [7][8]

References
  1. "Nichi-Iko Pharmaceutical Co., Ltd to Acquire Sagent Pharmaceuticals for $21.75 Per Share in All Cash Transaction (NASDAQ:SGNT)".
  2. "Sagent Pharmaceuticals Launches Full-Line Of Prefilled 6 mg And 12 mg Adenosine Syringes". www.pharmaceuticalonline.com. Retrieved 22 October 2019.
  3. "Form S-1 Amendment No. 3". www.sec.gov. Retrieved 22 October 2019.
  4. "Sagent Pharmaceuticals Announces Acquisition of Omega Laboratories (NASDAQ:SGNT)".
  5. Inc, Sagent Pharmaceuticals (26 September 2014). "Sagent Pharmaceuticals Announces the Launch of GLYDO(TM) (Lidocaine HCI Jelly USP, 2%)". GlobeNewswire News Room. Retrieved 22 October 2019.
  6. "Sagent Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Results (NASDAQ:SGNT)".
  7. Pharmaceuticals, Sagent. "Sagent Pharmaceuticals Announces Acquisition of Raleigh Manufacturing Site". www.prnewswire.com. Retrieved 22 October 2019.
  8. in-pharmatechnologist.com. "FDA approves Omega Laboratories for manufacturing". in-pharmatechnologist.com. Retrieved 22 October 2019.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.